<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04646161</url>
  </required_header>
  <id_info>
    <org_study_id>professor</org_study_id>
    <nct_id>NCT04646161</nct_id>
  </id_info>
  <brief_title>Prostaglandins Use Before Mirena IUD Insertion in Prev CS Women During Lactational Amenorrhea</brief_title>
  <official_title>Prostaglandins Use Before Mirena IUD Insertion in Prev CS Women During Lactational Amenorrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized controlled study to determine the effect of prostaglandin&#xD;
      intake before Mirena IUD insertion It was conducted at the Department of Obstetrics &amp;&#xD;
      Gynecology, Kasr El-Ainy Teaching Hospital, Faculty of Medicine, Cairo University,&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aiming to measure the estimate difficulty of insertion of the Mirena IUD by using&#xD;
      prostaglandins 2 hours before the procedure and the effect of prostaglandins to make this&#xD;
      procedure easy with other side effects and complications as bleeding perforation, nausea,&#xD;
      vomiting, failure of insertion and comparing them with a placebo group who didn't receive&#xD;
      prostaglandins&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Difficulty of insertion of Mirena IUD by using the Ease of Insertion score graduated as VAS like scale</measure>
    <time_frame>During the intervention</time_frame>
    <description>By using the visual analogue score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cervical dilataion &lt; 4 mm</measure>
    <time_frame>During the intervention</time_frame>
    <description>need for cervical dilatation to pass the IUD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at insertion according to VAS</measure>
    <time_frame>During the intervention</time_frame>
    <description>By using the visual analogue score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective sensation of satisfaction graduated as VAS like scale</measure>
    <time_frame>During the intervention</time_frame>
    <description>By using the visual analogue score like system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects during IUD insertion: bleeding, vasovagal reaction, cramps, nausea, perforation, vomiting</measure>
    <time_frame>During the intervention</time_frame>
    <description>Bleeding by using the soaked bads</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects after 24 hrs of IUD insertion: nausea, vomiting, cramps and hyperthermia</measure>
    <time_frame>During the first 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects after 30 days of IUD insertion: spotting, cramps, acute PID and expulsion</measure>
    <time_frame>After 30 days of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of insertion(min)</measure>
    <time_frame>During the intervention</time_frame>
    <description>From start of procedure till removing the speculum</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>to Study the Estimate Difficulty of Insertion Mirena IUD With Use of Prostaglandins</condition>
  <arm_group>
    <arm_group_label>prostaglandins before iud insertion group</arm_group_label>
    <description>this group will receive 200 mcg prostaglandins in form of misoprostol 2 hrs before mirena iud insertion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <description>this group will receive placebo tablet before mirena iud insertion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>misoprostol 200 mcg will be given sublingual 2 hrs before mirena iud insertion</description>
    <arm_group_label>prostaglandins before iud insertion group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        female patients during the lactational amenorrhea who undergo Mirena IUD insertion after&#xD;
        had been delivered by CS within 6 monthes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1- Women in lactational amenoeehea with pregnancy test negative 2- Women who had&#xD;
             caesarean section within 6 monthes of IUD insertion 3- No medical disorders&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1- Women in regular menses 2- Medical disorders 3- Nulligravida or muligravida with&#xD;
             NVD 4- Women with history of Previous CS more than one CS 5- Any congenital uterine&#xD;
             anomalies, fibroids and adenomysis 6- Chronic pelvic pain 7- Intrauterine adhesions 8-&#xD;
             Spasmodic dysmenohrrea 9- Allergy to misoprostol&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>hany saad, assisstant prof</last_name>
    <phone>01001817211</phone>
    <email>hanysaad25280@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>hadeer meshaal, assistant prof</last_name>
    <phone>01001435238</phone>
    <email>dr_hadeer@live.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>02</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hany saad, assistant prof</last_name>
      <phone>01001817211</phone>
      <email>hanysaad25280@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>hadeer meshaal, ass prof</last_name>
      <phone>01001435238</phone>
      <email>dr_hadeer@live.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 7, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2020</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Hany saad</investigator_full_name>
    <investigator_title>assisstant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

